Literature DB >> 23436714

Nanoparticles exposing neurotensin tumor-specific drivers.

Chiara Falciani1, Jlenia Brunetti, Barbara Lelli, Antonella Accardo, Diego Tesauro, Giancarlo Morelli, Luisa Bracci.   

Abstract

Nanoparticles have attracted much attention for their potential application as in vivo carriers of drugs. Labeling of nanoparticles with bioactive markers that are able to direct them toward specific biological target receptors has led to a new generation of drug delivery systems. In particular, low molecular weight peptides that remain stable in vivo could be promising tools to selectively drive nanoparticles loaded with active components to tumor cells. We reported, recently, that tetrabranched neurotensin peptides (NT4) may be used to selectively target tumor cells with liposomes. Liposomes functionalized with tetrabranched neurotensin peptide, NT4, and loaded with doxorubicin showed clear advantages in cell binding, anthracyclin internalization, and cytotoxicity in respect of not functionalized liposomes. In this study, we compare branched (NT4) versus linear (NT) peptides in the ability to drive liposomes to target cells and deliver their toxic cargo. We showed here that the more densely decorated liposomes had a better activity profile in terms of drug delivery. Presentation of peptides to the cell membranes in the grouped shape provided by branched structure facilitates liposome cell binding and fusion.
Copyright © 2013 European Peptide Society and John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23436714     DOI: 10.1002/psc.2493

Source DB:  PubMed          Journal:  J Pept Sci        ISSN: 1075-2617            Impact factor:   1.905


  13 in total

Review 1.  Nanoparticle ligand presentation for targeting solid tumors.

Authors:  Jason T Duskey; Kevin G Rice
Journal:  AAPS PharmSciTech       Date:  2014-06-14       Impact factor: 3.246

2.  A marine analgesic peptide, Contulakin-G, and neurotensin are distinct agonists for neurotensin receptors: uncovering structural determinants of desensitization properties.

Authors:  Hee-Kyoung Lee; Liuyin Zhang; Misty D Smith; Aleksandra Walewska; Nadeem A Vellore; Riccardo Baron; J Michael McIntosh; H Steve White; Baldomero M Olivera; Grzegorz Bulaj
Journal:  Front Pharmacol       Date:  2015-02-10       Impact factor: 5.810

3.  Neurotensin branched peptide as a tumor-targeting agent for human bladder cancer.

Authors:  Jlenia Brunetti; Chiara Falciani; Barbara Lelli; Andrea Minervini; Niccolò Ravenni; Lorenzo Depau; Giampaolo Siena; Eleonora Tenori; Stefano Menichetti; Alessandro Pini; Marco Carini; Luisa Bracci
Journal:  Biomed Res Int       Date:  2015-04-23       Impact factor: 3.411

4.  Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells.

Authors:  Paola Ringhieri; Silvia Mannucci; Giamaica Conti; Elena Nicolato; Giulio Fracasso; Pasquina Marzola; Giancarlo Morelli; Antonella Accardo
Journal:  Int J Nanomedicine       Date:  2017-01-13

5.  The GAG-specific branched peptide NT4 reduces angiogenesis and invasiveness of tumor cells.

Authors:  Luisa Bracci; Elisabetta Mandarini; Jlenia Brunetti; Lorenzo Depau; Alessandro Pini; Lucia Terzuoli; Silvia Scali; Chiara Falciani
Journal:  PLoS One       Date:  2018-03-22       Impact factor: 3.240

6.  Near-infrared quantum dots labelled with a tumor selective tetrabranched peptide for in vivo imaging.

Authors:  Jlenia Brunetti; Giulia Riolo; Mariangela Gentile; Andrea Bernini; Eugenio Paccagnini; Chiara Falciani; Luisa Lozzi; Silvia Scali; Lorenzo Depau; Alessandro Pini; Pietro Lupetti; Luisa Bracci
Journal:  J Nanobiotechnology       Date:  2018-03-03       Impact factor: 10.435

7.  Preclinical Evaluation of NHS-Activated Gold Nanoparticles Functionalized with Bombesin or Neurotensin-Like Peptides for Targeting Colon and Prostate Tumours.

Authors:  Livia Elena Chilug; Dana Niculae; Radu Anton Leonte; Alexandrina Nan; Rodica Turcu; Cosmin Mustaciosu; Radu Marian Serban; Vasile Lavric; Gina Manda
Journal:  Molecules       Date:  2020-07-24       Impact factor: 4.411

Review 8.  Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs.

Authors:  Antonella Accardo; Luigi Aloj; Michela Aurilio; Giancarlo Morelli; Diego Tesauro
Journal:  Int J Nanomedicine       Date:  2014-03-27

9.  Large set data mining reveals overexpressed GPCRs in prostate and breast cancer: potential for active targeting with engineered anti-cancer nanomedicines.

Authors:  Eric Kübler; Hugo Albrecht
Journal:  Oncotarget       Date:  2018-05-18

Review 10.  Utilizing Peptide Ligand GPCRs to Image and Treat Pancreatic Cancer.

Authors:  Gail L Matters; John F Harms
Journal:  Biomedicines       Date:  2018-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.